Skip to main content

Table 4 Patient characteristics by tumor histology

From: Prognostic effect of matrix metalloproteinase-9 in patients with resected Non small cell lung cancer

  Tumor MMP-9
Squamous cell carcinoma   Adenocarcinoma  
No Expression Expression P No Expression Expression P
N(%) N(%)   N(%) N(%)
Age    0.464    0.160
  Below median 64 (49.2) 25 (55.6)   57 (55.3) 45 (45.5)  
  Above median 66 (50.8) 20 (44.4)   46 (44.7) 54 (54.5)  
Sex    0.021    0.166
  Male 121 (93.1) 36 (80.8)   41 (39.8) 49 (49.5)  
  Female 9 (6.9) 9 (20.2)   62 (60.2) 50 (50.5)  
Stage    0.021    0.006
  I 65 (50.0) 15 (33.4)   77 (74.7) 55 (55.6)  
  II 49 (37.7) 19 (42.2)   15 (14.6) 24 (24.2)  
  IIIA 16 (12.3) 11 (24.4)   11 (10.7) 20 (20.2)  
T stage    0.042    0.019
  T1 29 (22.3) 4 (8.9)   42 (40.8) 24 (24.2)  
  T2 75 (57.7) 29 (64.5)   55 (53.3) 67 (67.7)  
  T3 25 (19.2) 10 (22.2)   5 (4.9) 5 (5.1)  
  T4 1 (0.8) 2 (4.4)   1 (1.0) 3 (3.0)  
N stage    0.183    0.008
  N0 93 (71.6) 28 (62.2)   90 (87.4) 68 (68.7)  
  N1 31 (23.8) 13 (28.9)   3 (2.9) 14 (14.1)  
  N2 6 (4.6) 4 (8.9)   10 (9.7) 17 (17.2)  
Lymphovascular invasion    0.832    0.740
  No 111 (85.4) 39 (86.7)   94 (91.3) 89 (89.9)  
  Yes 19 (14.6) 6 (13.3)   9 (8.7) 10 (10.1)  
Postoperative Treatment    0.299    0.001
  Chemotherapy 41 (31.5) 18 (40.0)   24 (22.3) 42 (42.4)  
  Radiation 7 (5.4) 1 (2.2)   0 1 (1.0)  
  Combination 10 (7.7) 6 (13.3)   7 (6.8) 13 (13.1)  
  No treatment 72 (55.4) 20 (44.4)   72 (69.9) 43 (43.4)  
  1. MMP-9: matrix metalloproteinase-9; Combination: Chemotherapy + Radiation therapy.